Longeveron Inc LGVN shares are trading higher Thursday after the company announced the publication of results from a Phase 1 trial testing Lomecel-B on patients with mild Alzheimer's disease in "Alzheimer's & Dementia: The Journal of the Alzheimer's Association."
The trial met its primary endpoint, demonstrating that Lomecel-B was well tolerated in this patient population. In addition, the data provided indications supporting further exploration of Lomecel-B, particularly the therapeutic potential to slow cognitive decline and improve quality of life in patients with Alzheimer's.
Longeveron is a a clinical-stage biopharma company developing cellular therapies for aging-related illnesses, chronic disorders and other specific life-threatening conditions.
See Also: EXCLUSIVE: Longeveron's Lomecel-B Data In Alzheimer's Disease Published In Medical Journal
LGVN 52-Week Range: $2.84 - $45.00
The stock was up 40.9% at $9.51 at time of publication, according to data from Benzinga Pro.
Photo: sbtlneet from Pixabay.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
